Last update 08 May 2025

Chengdu Ori Pharmaceutical Co., Ltd.

Private Company|2020|Sichuan Sheng, China|
www.origiant.com

Overview

Tags

Other Diseases
Neoplasms
Nervous System Diseases
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Nervous System Diseases2
Immune System Diseases1
Hemic and Lymphatic Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Chemical drugs1
Top 5 TargetCount
KRAS G12D(GTPase KRas G12D)1
MAP3K13 x RIPK11
RIPK3(receptor interacting serine/threonine kinase 3)1

Related

4
Drugs associated with Chengdu Ori Pharmaceutical Co., Ltd.
ORIC-1940
Target-
Mechanism-
Active Org.
Chengdu Ori Pharmaceutical Co., Ltd.
Originator Org.
Chengdu Ori Pharmaceutical Co., Ltd.
Active Indication
Lymphohistiocytosis, Hemophagocytic
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
KRAS G12D inhibitors(Ori Pharmaceutical)
Target
KRAS G12D
Mechanism
KRAS G12D inhibitors
Active Org.
Chengdu Ori Pharmaceutical Co., Ltd.
Originator Org.
Chengdu Ori Pharmaceutical Co., Ltd.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
CN118878535
Patent Mining
Target
MAP3K13 x RIPK1
Mechanism
MAP3K13 inhibitors [+1]
Active Org.
Chengdu Ori Pharmaceutical Co., Ltd.
Originator Org.
Chengdu Ori Pharmaceutical Co., Ltd.
Active Indication
Autoimmune Diseases [+3]
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Chengdu Ori Pharmaceutical Co., Ltd.
CTR20242774
/ Not yet recruitingPhase 1
评价注射用盐酸ORIC-1940在中国健康成人志愿者中单次/多次给药的安全性、耐受性及PK/PD特征的Ia期临床研究
[Translation] A Phase Ia clinical study to evaluate the safety, tolerability and PK/PD characteristics of single/multiple doses of ORIC-1940 hydrochloride for injection in healthy Chinese adult volunteers
CTR20243221
/ Not yet recruitingPhase 1
评估ORIC-1940在中国噬血细胞性淋巴组织细胞增多症经治患者中的安全性、耐受性、初步疗效和PK/PD特征的开放标签Ib期临床研究
[Translation] An open-label Phase Ib study to evaluate the safety, tolerability, preliminary efficacy, and PK/PD characteristics of ORIC-1940 in Chinese patients with previously treated hemophagocytic lymphohistiocytosis
100 Clinical Results associated with Chengdu Ori Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Chengdu Ori Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Chengdu Ori Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Chengdu Ori Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
1
Preclinical
Phase 1 Clinical
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free